FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2915221528> ?p ?o ?g. }

• W2915221528 abstract "Objective: To describe the long-term, real-life use of onabotulinumtoxinA for the symptomatic treatment of chronic migraine (CM) in a clinical setting over a 2-year period Background: The REPOSE Study, a European, multicenter, prospective, non-interventional study, investigated the effectiveness and safety of real-life use of onabotulinumtoxinA for chronic migraine (CM). Design/Methods: Adults prescribed onabotulinumtoxinA for CM were enrolled. Patients received onabotulinumtoxinA approximately every 12 weeks according to their physician’s usual practice, guided by the Summary of Product Characteristics. OnabotulinumtoxinA injection practices, safety, headache-day frequency, and Migraine Specific Quality of Life Questionnaire (MSQ) were collected at baseline and follow-up visits. Results: Among 644 patients enrolled, 633 patients received ≥1 onabotulinumtoxinA dose for a total of 3499 onabotulinumtoxinA treatments. Patients had a mean (SD) age of 45.4 (11.7) years, were typically women (85.3%) and had a mean of 20.6 headache days/month. The median dose and median number of injection sites of onabotulinumtoxinA per session (baseline up to follow-up session 8) were 155 U and 31 sites, respectively. Through follow-up session 8, patient-reported estimates of headache days/month (≥4 hours) were significantly reduced from baseline ( P Conclusions: Preventive treatment of CM with onabotulinumtoxinA in a longer-term (24-month) real-world setting sustains a reduction in the frequency of headache days and significantly improves quality of life relative to baseline. No new safety concerns were identified. Study Supported by: Allergan plc Disclosure: Dr. Ahmed has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Honorarium for consultancy and lecturing from Allergan, Eneura, Electrocore and Novartis, which is paid to the British Association for the Study of Headache and the Migraine Trust. Dr. Gaul has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Honoraria from Allergan Pharma, Ratiopharm, Boehringer Ingelheim Pharma, Lilly, Novartis Pharma, Desitin Arzneimittel, Cerbotec, Bayer vital, Hormosan Pharma, electroCore und Grunenthal, Reckitt Benckiser, TEVA. Dr. Martelletti has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Prof. Martelletti has received research grants, advisory board fees, or travel fees from ACRAF, Allergan S.p.A., Amgen Inc., electroCore, LLC, Novartis AG, and Teva Pharmaceutical Industries Ltd. Dr. Martelletti has received personal compensation in an editorial capacity for The Journal of Headache and Pain. Dr. Martelletti has received research support from Prof. Martelletti has received research grants, advisory board fees, or travel fees from ACRAF, Allergan S.p.A., Amgen Inc., electroCore, LLC, Novartis AG, and Teva Pharmaceutical Industries Ltd. Dr. Garcia Monco Carra has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Consulted for Allergan plc. Dr. Manack Adams has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan plc. Dr. Manack Adams holds stock and/or stock options in Allergan plc, which sponsored research in which Dr. Manack Adams was involved as an investigator. Dr. Manack Adams holds stock and/or stock options in Allergan plc." @default.
• W2915221528 created "2019-03-02" @default.
• W2915221528 creator A5002813586 @default.
• W2915221528 creator A5008323754 @default.
• W2915221528 creator A5015730759 @default.
• W2915221528 creator A5023925501 @default.
• W2915221528 creator A5069865671 @default.
• W2915221528 date "2018-04-10" @default.
• W2915221528 modified "2023-09-23" @default.
• W2915221528 title "Real-Life Use of OnabotulinumtoxinA for the Symptomatic Treatment of Chronic Migraine: The REPOSE Study (P4.150)" @default.
• W2915221528 hasPublicationYear "2018" @default.
• W2915221528 type Work @default.
• W2915221528 sameAs 2915221528 @default.
• W2915221528 citedByCount "0" @default.
• W2915221528 crossrefType "journal-article" @default.
• W2915221528 hasAuthorship W2915221528A5002813586 @default.
• W2915221528 hasAuthorship W2915221528A5008323754 @default.
• W2915221528 hasAuthorship W2915221528A5015730759 @default.
• W2915221528 hasAuthorship W2915221528A5023925501 @default.
• W2915221528 hasAuthorship W2915221528A5069865671 @default.
• W2915221528 hasConcept C126322002 @default.
• W2915221528 hasConcept C159110408 @default.
• W2915221528 hasConcept C168563851 @default.
• W2915221528 hasConcept C1862650 @default.
• W2915221528 hasConcept C187212893 @default.
• W2915221528 hasConcept C188816634 @default.
• W2915221528 hasConcept C197934379 @default.
• W2915221528 hasConcept C2778541695 @default.
• W2915221528 hasConcept C2779951463 @default.
• W2915221528 hasConcept C2910587157 @default.
• W2915221528 hasConcept C2992435398 @default.
• W2915221528 hasConcept C71924100 @default.
• W2915221528 hasConceptScore W2915221528C126322002 @default.
• W2915221528 hasConceptScore W2915221528C159110408 @default.
• W2915221528 hasConceptScore W2915221528C168563851 @default.
• W2915221528 hasConceptScore W2915221528C1862650 @default.
• W2915221528 hasConceptScore W2915221528C187212893 @default.
• W2915221528 hasConceptScore W2915221528C188816634 @default.
• W2915221528 hasConceptScore W2915221528C197934379 @default.
• W2915221528 hasConceptScore W2915221528C2778541695 @default.
• W2915221528 hasConceptScore W2915221528C2779951463 @default.
• W2915221528 hasConceptScore W2915221528C2910587157 @default.
• W2915221528 hasConceptScore W2915221528C2992435398 @default.
• W2915221528 hasConceptScore W2915221528C71924100 @default.
• W2915221528 hasOpenAccess W2915221528 @default.
• W2915221528 hasRelatedWork W2803840290 @default.
• W2915221528 hasRelatedWork W2805440854 @default.
• W2915221528 hasRelatedWork W2811121788 @default.
• W2915221528 hasRelatedWork W2886869311 @default.
• W2915221528 hasRelatedWork W2893072158 @default.
• W2915221528 hasRelatedWork W2893615962 @default.
• W2915221528 hasRelatedWork W2897284151 @default.
• W2915221528 hasRelatedWork W2900030708 @default.
• W2915221528 hasRelatedWork W2916037536 @default.
• W2915221528 hasRelatedWork W2950025797 @default.
• W2915221528 hasRelatedWork W2982561889 @default.
• W2915221528 hasRelatedWork W3006211681 @default.
• W2915221528 hasRelatedWork W3093820723 @default.
• W2915221528 hasRelatedWork W3102246766 @default.
• W2915221528 hasRelatedWork W3147125336 @default.
• W2915221528 hasRelatedWork W3188120653 @default.
• W2915221528 hasRelatedWork W3191369108 @default.
• W2915221528 hasRelatedWork W3197720978 @default.
• W2915221528 hasRelatedWork W3200119531 @default.
• W2915221528 hasRelatedWork W3210087989 @default.
• W2915221528 hasVolume "90" @default.
• W2915221528 isParatext "false" @default.
• W2915221528 isRetracted "false" @default.
• W2915221528 magId "2915221528" @default.
• W2915221528 workType "article" @default.